Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G) Meeting Abstract
| Authors: | Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A. |
| Abstract Title: | Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G) |
| Meeting Title: | 13th World Conference on Lung Cancer (IASLC) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 4 |
| Issue: | 9 Suppl. 1 |
| Meeting Dates: | 2009 Jul 31-Aug 4 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2009-09-01 |
| Start Page: | S687 |
| Language: | English |
| ACCESSION: | ISI:000269496002160 |
| PROVIDER: | wos |
| PUBMED: | 19704333 |
| DOI: | 10.1097/JTO.0b013e3181b9c77e |
| Notes: | --- - Meeting Abstract P1.192 - Suppl. 1 - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
